During the last session, Xilio Therapeutics Inc (NASDAQ:XLO)’s traded shares were 0.55 million, with the beta value of the company hitting -0.24. At the end of the trading day, the stock’s price was $1.10, reflecting an intraday gain of 2.80% or $0.03. The 52-week high for the XLO share is $1.93, that puts it down -75.45 from that peak though still a striking 54.55% gain since the share price plummeted to a 52-week low of $0.50. The company’s market capitalization is $50.29M, and the average intraday trading volume over the past 10 days was 1.66 million shares, and the average trade volume was 475.40K shares over the past three months.
Xilio Therapeutics Inc (XLO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.33. XLO has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Xilio Therapeutics Inc (NASDAQ:XLO) trade information
Xilio Therapeutics Inc (XLO) registered a 2.80% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.80% in intraday trading to $1.10, hitting a weekly high. The stock’s 5-day price performance is 12.82%, and it has moved by 7.84% in 30 days. Based on these gigs, the overall price performance for the year is 61.79%. The short interest in Xilio Therapeutics Inc (NASDAQ:XLO) is 0.12 million shares and it means that shorts have 0.93 day(s) to cover.
The consensus price target of analysts on Wall Street is $7, which implies an increase of 84.29% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7 and $7 respectively. As a result, XLO is trading at a discount of -536.36% off the target high and -536.36% off the low.
Xilio Therapeutics Inc (XLO) estimates and forecasts
Statistics show that Xilio Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Xilio Therapeutics Inc (XLO) shares have gone up 22.91% during the last six months, with a year-to-date growth rate more than the industry average at 58.99% against 16.80.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -44.91%. While earnings are projected to return 58.99% in 2025.
XLO Dividends
Xilio Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Xilio Therapeutics Inc (NASDAQ:XLO)’s Major holders
Xilio Therapeutics Inc insiders own 38.89% of total outstanding shares while institutional holders control 28.36%, with the float percentage being 46.41%. BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC is the largest shareholder of the company, while 34.0 institutions own stock in it. As of 2024-06-30, the company held over 3.79 million shares (or 13.5618% of all shares), a total value of $3.59 million in shares.
The next largest institutional holding, with 3.0 million shares, is of ROCK SPRINGS CAPITAL MANAGEMENT LP’s that is approximately 10.7595% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $2.85 million.
